Tailstorm Health, Inc., Phoenix, AZ
Is Tailstorm Health, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does Tailstorm Health, Inc. hold a Arizona pharmacy license?
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Has Tailstorm Health, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Apr 8, 2025), 1 warning letter close-out (Mar 23, 2026) and 2 FMD-145 letters (Mar 19, 2026 and Mar 20, 2026) for Tailstorm Health, Inc. State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Tailstorm Health, Inc.
- Location
- Phoenix, AZ
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Mar 23, 2026
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Tailstorm Health, Inc., a 503B facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Mar 23, 2026 | Warning letter close-out | Warning Letter Close Out Issued 03/23/2026 | fda.gov |
| Mar 20, 2026 | FMD-145 letter | FMD-145 Letter Issued 03/20/2026 | Not linked by FDA |
| Mar 19, 2026 | FMD-145 letter | FMD-145 Letter Issued 03/19/2026 | Not linked by FDA |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 8, 2025 | Warning letter | Warning Letter Issued 04/08/2025 | fda.gov |
| Oct 10, 2024 | Form 483 | 483 Issued 10/10/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
The dashboard does list Tailstorm Health, Inc, Chandler, AZ (FEI 3015929581): same name and state, different city, so not treated as this site.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 3, 2025 to Nov 14, 2025: 3 observations
- Firm on the cover
- Tailstorm Health Inc dba Medivant Health, 24416 N 19th Ave Ste 200, Phoenix, AZ 85085-1400
- FEI number
- 3022483154
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P. 0. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Established laboratory control mechanisms are not followed.
Specifically,
Your firm does not have an established system suitability procedure. Your firm performs the Light Obscuration Particle Count Test using your <Redacted B4> Particle Count {<Redacted B4>PC) for finished drug product release testing. However, your firm has not conducted method suitability testing for bevacizumab (Avastin) sterile intravitreal pre-filled syringes.
Your firm utilizes the <Redacted B4> Technique to test for particle matter for sterile intravitreal injectables, including bevacizumab (Avastin) pre-filled syringes, lot D25 110 (BUD: l 7/SEP/2026).
Observation 2
Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.
Specifically,
Your firm does not have an established procedure for the review of audit trails to ensure the reliability of your analytical testing data. Your Quality unit did not review audit trails. Your batch record checklist does not include confirmatory documentation that audit trails in your analytical instruments and software were reviewed and evaluated as part of batch release.
your analytical testing data. Your Quality unit did not review audit trails. Your batch record checklist does not include confinnato1y documentation that audit trails in your analytical instmments and software were reviewed and evaluated as pa1t of batch release.
Your firm utilizes the <Redacted B4> Particle Count {<Redacted B4>PC) to test for particule matter for your finished sterile drug products.
Since October 2024, your Quality unit released at leastL _ (6) (-4) Ibatches of bevacizumab (Avastin) pre-filled syringes, tirzapetide pre-filled syringes, and semaglutide pre-filled syrmges.
FACILITIES AND EQUIPMENT SYSTEM
Observation 3
Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.
Specifically,
On 11/11/2025, during the filling of bevacizumab (Avastin), lot D25120, I observed an unidentified white string on the ceiling of the ISO <Redacted B4> filling room. The condition of the ceiling surface presents a potential source of particulate contamination within the classified area used for aseptic processing.
Linked 483s whose text is not shown
- Oct 10, 2024: FDA document 184179: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
GLP-1 records under the same name: Tailstorm Health Inc. dba Medivant Health. More than one pharmacy page shares that name, so those records are not attributed to this location.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 11 products naming semaglutide and tirzepatide under the labeler name “Tailstorm Health INC”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (11). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 81483-0045 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .25 mg/.05 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0046 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .5 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0047 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0048 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1.7 mg/.22 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0049 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.4 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0050 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 2.4 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0051 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 5 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0052 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 7.5 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0053 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 10 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0054 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 12.5 mg/.25 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0055 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 15 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.